Roche will halt development of ocrelizumab for rheumatoid arthritis

Roche Holding plans to stop developing ocrelizumab as a treatment for rheumatoid arthritis because the drug's risk profile proved to be unfavorable when compared with existing treatments in an effectiveness and safety review. Roche said midstage trials of the drug, co-developed by Biogen Idec, for relapsing remitting multiple sclerosis are ongoing.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC